Payment overview · 2025
General Payments
$435.17
19 reported records · 8 companies
Healthcare provider profile · identity verified
Amber Sullivan, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MARTINSBURG, WV · NPI 1821342999
Verified facts
What the public records show
CMS Open Payments records show Amber Sullivan, CRNP received $435.17 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $127.31 | 29.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.47 | 21.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.62 | 13.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.17 | 11.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.30 | 10.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.19 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.16 | 4.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.95 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $390.17 | 18 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $127.31 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $97.46 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $94.47 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.17 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.17 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.17 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $47.30 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 101 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 44 |
| Gabapentin | Gabapentin | 165 | 40 |
| Lisinopril | Lisinopril | 164 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 38 |
| Tramadol Hcl | Tramadol Hcl | 149 | 29 |
| Montelukast Sodium | Montelukast Sodium | 146 | 29 |
| Furosemide | Furosemide | 139 | 34 |
| Losartan Potassium | Losartan Potassium | 133 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 35 |
| Omeprazole | Omeprazole | 121 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 29 |
| Meloxicam | Meloxicam | 109 | 25 |
| Famotidine | Famotidine | 104 | 25 |
| Mounjaro | Tirzepatide | 101 | 20 |
| Sertraline Hcl | Sertraline Hcl | 100 | 19 |
| Potassium Chloride | Potassium Chloride | 96 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 85 | 19 |
| Metformin Hcl | Metformin Hcl | 81 | 25 |
| Diazepam | Diazepam | 78 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 19 |
| Baclofen | Baclofen | 76 | 21 |
| Ezetimibe | Ezetimibe | 76 | 21 |
| Simvastatin | Simvastatin | 76 | 20 |
| Alprazolam | Alprazolam | 73 | 13 |
| Buspirone Hcl | Buspirone Hcl | 73 | 19 |
| Lorazepam | Lorazepam | 73 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 15 |
| Trazodone Hcl | Trazodone Hcl | 70 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 13 |
| Pregabalin | Pregabalin | 65 | 11 |
| Temazepam | Temazepam | 65 | 14 |
| Carvedilol | Carvedilol | 64 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 11 |
| Atenolol | Atenolol | 59 | 17 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Eliquis | Apixaban | 55 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 14 |
| Ozempic | Semaglutide | 52 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Desloratadine | Desloratadine | 46 | 11 |
| Meclizine Hcl | Meclizine Hcl | 46 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 15 |
| Methylprednisolone | Methylprednisolone | 44 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | 13 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 16 |
| Prednisone | Prednisone | 40 | 21 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Nystatin | Nystatin | 38 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 17 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 13 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Fluconazole | Fluconazole | 26 | 14 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Glipizide | Glipizide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.17 · 19 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, FARXIGA, Kerendia, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error